Home > Oncology > ASCO 2019 > Lung Cancer > Repotrectinib shows encouraging safety, efficacy for patients with ROS1+ NSCLC

Repotrectinib shows encouraging safety, efficacy for patients with ROS1+ NSCLC

Presented By
Dr Byoung Chul Cho, Yonsei Cancer Centre, South Korea
Conference
ASCO 2019
Trial
TRIDENT-1
Medical writer: Emily Kuhl, PhD Early results from the first-in-human phase I/II clinical trial of the tyrosine kinase inhibitor (TKI) repotrectinib, presented May 31 (Abstract 9011), suggest that the novel drug is both well tolerated and efficacious for patients with advanced ROS1 fusion–positive non–small cell lung cancer (NSCLC). These findings are important because TKIs, like all targeted therapies, are limited by drug resistance; however, repotrectinib was developed to overcome treatment-resistant mutations. Study investigator Byoung Chul Cho, MD, PhD, of Yonsei Cancer Centre, Yonsei University College of Medicine, South Korea, presented the preliminary analyses. Repotrectinib is a next-generation, macrocyclic TKI designed for potent selectivity against tumours with ROS1, tropomyosin receptor kinase (TRK), and ALK rearrangements. Preclinical studies thus far appear to support the robust activity of repotrectinib against ROS1 fusion–positive re...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on